Meissa is a private biotech company focused on the advancement of vaccines for respiratory viruses. Meissa was founded on proprietary technologies employing reverse genetics for rational design of more effective live attenuated vaccines. The technology is exclusively licensed from Emory University and Children’s Healthcare of Atlanta. Dr. Moore, together with Dr. Roderick Tang, a vaccine biotech expert, co-founded Meissa. They are supported by a team with extensive experience in all aspects of vaccine development. Meissa is currently a resident company at the Johnson & Johnson Innovation – JLABS in South San Francisco.
Location: United States, California, Redwood City
Employees: 11-50
Total raised: $33.4M
Founded date: 2014
Investors 1
| Date | Name | Website |
| - | FundRx | fundrx.com |
Funding Rounds 2
| Date | Series | Amount | Investors |
| 27.09.2019 | Series A | $30M | - |
| 28.03.2019 | - | $3.4M | - |
Mentions in press and media 12
| Date | Title | Description |
| 28.10.2021 | A nasal COVID-19 vaccine could be the solution to ending the pandemic, experts say, and early trial data looks promising | Meissa is developing a nasal vaccine against COVID-19. But it’s still in the earliest phase of human testing. Meissa Vaccines COVID-19 vaccines are great at preventing severe illnesses and death. But they don’t always stop transmission or m... |
| 19.07.2021 | Meissa Vaccines’ leg up in the Covid-19 vaccines chase goes through the nose | In the landscape of mostly injectable Covid-19 vaccines and therapeutics, Meissa Vaccines stands out with its intranasal approach. The company contends that the more patient-friendly dosing option isn’t its only advantage. Easier and more e... |
| 27.09.2019 | Meissa Vaccines Closes $30M Financing | Meissa Vaccines, a South San Francisco, CA-based biotechnology company developing vaccines to prevent viral respiratory infections, closed a $30m Series A financing. Morningside Ventures made the investment. In conjunction with the deal, Is... |
| 27.09.2019 | Meissa Vaccines Closes $30M in Series A | SOUTH SAN FRANCISCO, CA, Meissa Vaccines has closed a $30 million Series A financing. >> Click here for more funding data on Meissa Vaccines >> To export Meissa Vaccines funding data to PDF and Excel, click here Meissa Va... |
| 26.09.2019 | Meissa raises $30M to take RSV vaccine into the clinic | Meissa Vaccines has raised $30 million to advance a pipeline of vaccines to prevent viral respiratory infections. The series A equips Meissa to run phase 1 and 2 trials of a respiratory syncytial virus (RSV) vaccine while moving other candi... |
| 28.03.2019 | Meissa Vaccines Closes $3.4M Financing Round | Meissa Vaccines, a South San Francisco, CA-based biotechnology company developing vaccines to prevent viral respiratory infections, closed a $3.4m seed funding round. The financing included numerous undisclosed individual investors. The com... |
| 07.08.2017 | Term Sheet — Monday, Aug. 7 | STUPID AMOUNTS OF MONEY Good morning! Three quick things: Paid Content How can you protect what you can't see? From ExtraHop To wildly understate things, a SoftBank deal would be complicated. SoftBank is already invested in pretty much all ... |
| 06.08.2017 | FundRx backs Meissa Vaccines | Meissa Vaccines, a start-up biotechnology company developing vaccines to prevent viral respiratory infections, announced that it has received a seed investment from FundRx, an innovative healthcare & life sciences venture capital platfo... |
| 03.08.2017 | Meissa Vaccines Raises Seed Funding Round | Meissa Vaccines, a South San Francisco, CA-based biotechnology startup developing vaccines to prevent viral respiratory infections, received a seed funding from FundRx, an innovative healthcare & life sciences venture capital platform b... |
| - | Drug companies have prepared no COVID vaccines to target future variants — and that should terrify us | This story is available exclusively to Insider subscribers. Become an Insider and start reading now. When COVID-19 first began its deadly advance in late 2019, something alarming happened. Not one of the world's top vaccine makers was able ... |
Show more